Literature DB >> 1754787

Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis.

J Redington1, S C Ebert, W A Craig.   

Abstract

The pharmacokinetic and pharmacodynamic properties of antimicrobial agents used for surgical prophylaxis are reviewed. Since levels in tissue homogenates depend on the amount of drug present intracellularly, they do not accurately describe the relation between concentrations in serum and those in interstitial fluid. Levels of free drug in serum are good predictors of the time course of concentrations of unbound drug in interstitial fluid. An increase in protein binding does not reduce the area under the curve (AUC) of free drug for beta-lactam agents eliminated predominantly by glomerular filtration. Pharmacodynamic studies of persistent growth suppression and bactericidal activity predict that the period for which the free-drug concentration exceeds the minimal inhibitory concentration (MIC) is an important parameter in the efficacy of beta-lactam antibiotics. In contrast, the AUC is the major parameter in the efficacy of aminoglycosides and quinolones. Although studies with animals support the above concepts, data for humans are limited. Until additional clinical trials dictate other conclusions, the goal of prophylaxis with beta-lactam agents should be to provide serum levels of free drug above the MIC for common contaminating bacteria for the entire surgical period.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1754787     DOI: 10.1093/clinids/13.supplement_10.s790

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

1.  Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

Authors:  Gerald J Fetterly; Christine M Ong; Sujata M Bhavnani; Jeffrey S Loutit; Steven B Porter; Lisa G Morello; Paul G Ambrose; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  J A Bilello; P A Bilello; K Stellrecht; J Leonard; D W Norbeck; D J Kempf; T Robins; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.

Authors:  Philippe Moreillon; Walter R Wilson; Roland Leclercq; José M Entenza
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

Review 4.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients.

Authors:  M Dupon; G Janvier; G Vinçon; S Winnock; F Demotes-Mainard; O Capeyron; J Saric
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery.

Authors:  A R Gascón; E Campo; R M Hernández; B Calvo; J Errasti; J L Pedraz
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

7.  Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients.

Authors:  P M Arnow; K Furmaga; J P Flaherty; D George
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.

Authors:  Silvia Garazzino; Alessandro Aprato; Lorena Baietto; Antonio D'Avolio; Agostino Maiello; Francesco Giuseppe De Rosa; Domenico Aloj; Marco Siccardi; Antonio Biasibetti; Alessandro Massè; Giovanni Di Perri
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 9.  Parenteral aminoglycoside therapy. Selection, administration and monitoring.

Authors:  C R Kumana; K Y Yuen
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.